Literature DB >> 11804670

Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing.

Bartholomeus Johannes Veldt1, Fabrice Lainé, Anne Guillygomarc'h, Laurence Lauvin, Karim Boudjema, Michel Messner, Pierre Brissot, Yves Deugnier, Romain Moirand.   

Abstract

BACKGROUND/AIMS: The aim of our study was to evaluate the proportion of patients with severe alcoholic cirrhosis who would need orthotopic liver transplantation (OLT) and to determine the optimal delay to evaluate an abstinent patient for transplantation.
METHODS: Survival without OLT, improvement in liver function and need for OLT were studied in all patients admitted in 1997 for a first episode of Child-Pugh C alcoholic cirrhosis.
RESULTS: Twenty-six percent (19/74) of patients died during the initial hospitalization. The cumulative survival rates after 6 months and 1, 2 and 3 years were 56, 36, 35 and 24%, respectively. One liver transplantation (1.3%, 95% confidence interval 0.0-3.9) was performed for persisting liver failure despite abstinence. Improvement of the Child-Pugh score was observed within 3 months in 66% of the abstinent patients. OLT was indicated in four patients without liver improvement despite abstinence, but was contraindicated in three.
CONCLUSIONS: Only a few patients with severe alcoholic cirrhosis undergo OLT, since most of them do not stop drinking and/or die soon, and those becoming abstinent often improve their liver function. OLT should be considered when improvement in liver function is lacking after 3 months of abstinence.

Entities:  

Mesh:

Year:  2002        PMID: 11804670     DOI: 10.1016/s0168-8278(01)00228-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  34 in total

1.  Studies on avian erythrocyte metabolism--I. Procedure for separation and quantitation of the major phosphorylated metabolic intermediates by anion exchange chromatography.

Authors:  R E Isaacks; D R Harkness; G A Froeman; S A Sussman
Journal:  Comp Biochem Physiol A Comp Physiol       Date:  1976-01

2.  Transplantation for alcoholic liver disease: lessons from the explant?

Authors:  A Bathgate; P Hayes
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

3.  Living donor liver transplantation for patients with alcoholic liver disease.

Authors:  Yo-Han Park; Shin Hwang; Chul-Soo Ahn; Ki-Hun Kim; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Gil-Chun Park; Jung-Man Namgoong; Hyung-Woo Park; Chun-Soo Park; Sung-Hwa Kang; Bo-Hyeon Jung; Sung-Gyu Lee
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2013-02-28

Review 4.  Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination?

Authors:  Moon-Sun Kim; Madeleine Ong; Xianqin Qu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 5.  Long-term survival after liver transplantation for alcoholic liver disease.

Authors:  Paula Iruzubieta; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 6.  Microbiota-based treatments in alcoholic liver disease.

Authors:  Hotaik Sung; Seung Woo Kim; Meegun Hong; Ki Tae Suk
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

Review 7.  Alcoholic liver disease: treatment.

Authors:  Ki Tae Suk; Moon Young Kim; Soon Koo Baik
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

8.  Treatment of alcoholic liver disease.

Authors:  Thomas H Frazier; Abigail M Stocker; Nicole A Kershner; Luis S Marsano; Craig J McClain
Journal:  Therap Adv Gastroenterol       Date:  2011-01       Impact factor: 4.409

9.  Diagnosis and therapy of ascites in liver cirrhosis.

Authors:  Erwin Biecker
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

10.  Predictors of Mortality in Long-Term Follow-Up of Patients with Terminal Alcoholic Cirrhosis: Is It Time to Accept Remodeled Scores?

Authors:  Mirjana M Radisavljevic; Goran B Bjelakovic; Aleksandar V Nagorni; Miroslav P Stojanovic; Milan D Radojkovicn; Jasna Z Jovic; Aleksandra M Ignjatovic; Misa M Radisavljevic; Maja M Simonovic
Journal:  Med Princ Pract       Date:  2016-09-27       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.